A light-triggerable formulation to control the stability of pro-angiogenic transcription factor hypoxia inducible factor-1α (HIF-1α)
Source abstract
Abstract
The control of vascular remodeling mediated by transcription factor HIF-1α is critical in the treatment of several diseases including cancer, retinopathies, chronic wounds, and ischemic heart disease, among others. Gene silencing using a small interfering RNA (siRNA) is a promising therapeutic strategy to regulate HIF-1α; however, the delivery systems developed so far have limited endothelial targeting and efficiency. Herein, we have synthesized a light-triggerable polymeric nanoparticle (NP) library composed of 110 formulations which showed variable morphology, charge and disassembly rates after UV exposure. More than 35% of the formulations of the library were more efficient in gene knockdown than the siRNA delivered by a commercial transfection agent (lipofectamine RNAiMAX). The most efficient siRNA delivery formulations were tested against different cell types to identify one with preferential targeting to endothelial cells. Using a two-step methodology, we have identified a formulation that shows exquisite targeting to endothelial cells and is able to deliver more efficiently the siRNA that modulates HIF-1α than commercial transfection agents. Overall, the strategy reported here increases the specificity for tissue regulation and the efficiency for the intracellular delivery of siRNAs.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Neuroscience and Cell Biology
University of Coimbra
Coimbra
Portugal
Faculty of Medicine
Funding
Horizon 2020 Framework Programme · Fundação para a Ciência e a Tecnologia
References (44)
Show source-provided references
1. Semenza · Cell · 2012 · 148 · 39910.1016/j.cell.2012.01.021 ↗
2. Botusan · Proc. Natl. Acad. Sci. U. S. A. · 2008 · 105 · 1942610.1073/pnas.0805230105 ↗
3. Sarkar · Proc. Natl. Acad. Sci. U. S. A. · 2009 · 106 · 1876910.1073/pnas.0910561106 ↗
4. Semenza · Annu. Rev. Physiol. · 2014 · 76 · 3910.1146/annurev-physiol-021113-170322 ↗
5. Fraisl · Nat. Rev. Drug Discovery · 2009 · 8 · 13910.1038/nrd2761 ↗
6. Martin · Adv. Healthcare Mater. · 2016 · 5 · 275110.1002/adhm.201600820 ↗
7. Nelson · Adv. Mater. · 2014 · 26 · 60710.1002/adma.201303520 ↗
8. Bordoli · Oncogene · 2011 · 30 · 54810.1038/onc.2010.433 ↗
9. Mazzone · Cell · 2009 · 136 · 83910.1016/j.cell.2009.01.020 ↗
10. Wong · EMBO J. · 2017 · 36 · 218710.15252/embj.201696150 ↗
11. Miller · Nano Res. · 2018 · 11 · 531010.1007/s12274-018-2099-4 ↗
12. Kanasty · Nat. Mater. · 2013 · 12 · 96710.1038/nmat3765 ↗
13. Shukla · Mol. Pharm. · 2014 · 11 · 339510.1021/mp500426r ↗
14. Akinc · Nat. Biotechnol. · 2008 · 26 · 56110.1038/nbt1402 ↗
15. Love · Proc. Natl. Acad. Sci. U. S. A. · 2010 · 107 · 186410.1073/pnas.0910603106 ↗
16. Mahon · Bioconjugate Chem. · 2010 · 21 · 144810.1021/bc100041r ↗
17. Whitehead · Mol. Ther. · 2011 · 19 · 168810.1038/mt.2011.141 ↗
18. Kim · Adv. Drug Delivery Rev. · 2016 · 104 · 6110.1016/j.addr.2016.06.011 ↗
19. EBioMedicine , 2018, 34 , 1, 10.1016/j.ebiom.2018.08.02510.1016/j.ebiom.2018.08.025 ↗
20. Lonn · Sci. Rep. · 2016 · 6 · 3230110.1038/srep32301 ↗
21. Dahlman · Nat. Nanotechnol. · 2014 · 9 · 64810.1038/nnano.2014.84 ↗
22. Sahay · Nat. Biotechnol. · 2013 · 31 · 65310.1038/nbt.2614 ↗
23. Gilleron · Nat. Biotechnol. · 2013 · 31 · 63810.1038/nbt.2612 ↗
24. Wittrup · Nat. Biotechnol. · 2015 · 33 · 87010.1038/nbt.3298 ↗
25. Kozielski · ACS Nano · 2014 · 8 · 323210.1021/nn500704t ↗
26. Akinc · Bioconjugate Chem. · 2003 · 14 · 97910.1021/bc034067y ↗
27. Dvir · Nano Lett. · 2010 · 10 · 25010.1021/nl903411s ↗
28. Tiyaboonchai · J. Pharm. Sci. · 2001 · 90 · 90210.1002/jps.1042 ↗
29. Zhang · Adv. Mater. · 2009 · 21 · 41910.1002/adma.200801393 ↗
30. Venkataraman · Adv. Drug Delivery Rev. · 2011 · 63 · 122810.1016/j.addr.2011.06.016 ↗
31. Oh · Int. J. Nanomed. · 2014 · 9 · 51
32. Chou · Chem. Soc. Rev. · 2011 · 40 · 23310.1039/C0CS00003E ↗
33. Walkey · J. Am. Chem. Soc. · 2012 · 134 · 213910.1021/ja2084338 ↗
34. Xia · ACS Nano · 2008 · 2 · 8510.1021/nn700256c ↗
35. Lino · ACS Nano · 2018 · 12 · 520710.1021/acsnano.7b07538 ↗
36. Forsythe · Mol. Cell Biol. · 1996 · 16 · 460410.1128/MCB.16.9.4604 ↗
37. Carmeliet · Nature · 1998 · 394 · 48510.1038/28867 ↗
38. Ryan · EMBO J. · 1998 · 17 · 300510.1093/emboj/17.11.3005 ↗
39. Zhang · PLoS One · 2015 · 10 · e013462910.1371/journal.pone.0134629 ↗
40. Blersch · Angew. Chem., Int. Ed. Engl. · 2020 · 59 · 198510.1002/anie.201911398 ↗
41. Krock · Genes Cancer · 2011 · 2 · 111710.1177/1947601911423654 ↗
42. van Meeteren · Cell Tissue Res. · 2012 · 347 · 17710.1007/s00441-011-1222-6 ↗
43. Pintucci · FASEB J. · 2002 · 16 · 59810.1096/fj.01-0815fje ↗
44. Calvani · Blood · 2006 · 107 · 270510.1182/blood-2005-09-3541 ↗